Futuximab

Futuximab (992 DS) (INN) is a chimeric monoclonal antibody designed for the treatment of cancer.[1] It acts as an immunomodulator and also binds to HER1.[2][3]

Futuximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
TargetHER1
Clinical data
Other names992 DS
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6468H10002N1724O2055S46
Molar mass146269.94 g·mol−1

This drug was developed by Symphogen.

References



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.